Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca Acquires Caelum Biosciences | Contract Pharma

What are you searching for?

Sign in
Breaking News

AstraZeneca Acquires Caelum Biosciences

AstraZeneca will advance and accelerate ongoing Phase III development of CAEL-101, a potential first-in-class medicine for AL amyloidosis.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Fortress Biotech, Inc., a biopharmacompany focused on acquiring, developing and commercializing promising products and product candidates cost-effectively, and a company it founded, Caelum Biosciences, Inc., a biotechnology company developing treatments for rare and life-threatening diseases, closed AstraZeneca’s acquisition of Caelum for approximately $150 million.
 
The agreement also provides for additional potential payments to Caelum stockholders totaling up to $350 million, payable upon the achievement of regulatory and commercial milestones.
Caelum has two ongoing Phase 3 clinical trials for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis.

AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys, causing significant organ damage and failure that may ultimately be fatal.

CAEL-101 is currently being evaluated in the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical program in combination with standard-of-care (SoC) therapy in AL amyloidosis. Two parallel Phase III trials in patients with Mayo stage IIIa disease and in patients with Mayo stage IIIb disease respectively are ongoing.
 
Fortress is eligible to receive approximately 43 percent of all proceeds from the transaction.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics